Biogen Non-GAAP EPS of $5.25 beats by $1.16, revenue of $2.59B beats by $110M, raises FY22 guidance
Biogen press release  (NASDAQ:BIIB): Q2  Non-GAAP EPS of $5.25  beats by $1.16.
Revenue of $2.59B (-6.8% Y/Y)  beats by $110M.

FY22 Outlook:Â Revenue of $9.9B-$10.1B from prior outlook of $9.7B-$10B vs. consensus of $9.84B.
Non-GAAP EPS of $15.25-$16.75 from prior outlook of $14.25-$16.00 vs. consensus of $15.52.
Non-GAAP R&D expense is expected to be between $2.2 billion and $2.3 billion, unchanged from prior guidance.
Non-GAAP SG&A expense is expected to be between $2.3 billion and $2.4 billion, unchanged from prior guidance.
The Non-GAAP tax rate for 2022 is expected to be between 15.5% and 16.5%, unchanged from prior guidance.